From the FDA Drug Label
CONTRAINDICATIONS None. (4) The contraindications for Lokelma (sodium zirconium cyclosilicate) are none 1.
From the Research
Lokelma (sodium zirconium cyclosilicate) is contraindicated in patients with a history of hypersensitivity to the drug or any of its components, as well as in patients with severe constipation, bowel obstruction, or impaction, due to the potential for worsening these conditions 2. The medication should be used with caution in patients with conditions that predispose to constipation, as Lokelma may cause or worsen this side effect. Key considerations for the use of Lokelma include:
- Severe renal impairment or end-stage renal disease, which may increase the risk of developing hyperkalemia 3
- Potential interactions with other oral medications, which can be mitigated by administering Lokelma at least 2 hours apart from other medications 4
- Radiopacity on CT imaging, which can be a consideration for patients undergoing imaging studies 5 It is essential to carefully evaluate the potential benefits and risks of Lokelma in each patient, taking into account their individual medical history and current health status, as supported by studies such as the 12-month phase 3 study 3 and the open-label extension of the HARMONIZE study 6.